| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1089-3261(03)00105-3 |
| P698 | PubMed publication ID | 14594135 |
| P2093 | author name string | Nora V Bergasa | |
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Cholecystokinin antianalgesia: safety cues abolish morphine analgesia | Q28251132 | ||
| Effects of long-term rifampicin administration in primary biliary cirrhosis | Q28319860 | ||
| Rifampin-Induced Methadone Withdrawal | Q28342068 | ||
| Effect of cholestyramine on bile acid metabolism in normal man | Q28364623 | ||
| Defining and measuring fatigue | Q33542308 | ||
| Cannabinoids as potential new analgesics | Q33720144 | ||
| Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis | Q33851658 | ||
| Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain | Q33874423 | ||
| Cholestatic liver diseases and health-related quality of life | Q33891059 | ||
| Quality of life measurement in gastrointestinal and liver disorders | Q34001406 | ||
| Effect of stanozolol on itching in primary biliary cirrhosis | Q34166986 | ||
| Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys | Q34358508 | ||
| Raised histamine concentrations in chronic cholestatic liver disease | Q34391787 | ||
| Role of plasmapheresis in primary biliary cirrhosis | Q34526543 | ||
| Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions | Q34764961 | ||
| Expression cloning of a rat liver Na(+)-independent organic anion transporter | Q34907393 | ||
| Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease | Q35356375 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Opioid peptides and primary biliary cirrhosis | Q35706319 | ||
| The pruritus of cholestasis: from bile acids to opiate agonists | Q37879905 | ||
| Serotonin receptor "families" in the central nervous system: an overview | Q38004413 | ||
| Serotonin and nociception | Q38004465 | ||
| Itching after epidural and spinal opiates | Q39220178 | ||
| Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron | Q39476222 | ||
| Subhypnotic doses of propofol relieve pruritus associated with liver disease | Q39496761 | ||
| Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis | Q39531409 | ||
| Letter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine | Q39589240 | ||
| Phenobarbital Effects in Cholestatic Liver Disease | Q39589574 | ||
| Intravenous lignocaine for relief of intractable itch | Q39591679 | ||
| Saturable transport of peptides across the blood-brain barrier | Q39666983 | ||
| The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids | Q40513479 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats | Q40834414 | ||
| A controlled trial of naloxone infusions for the pruritus of chronic cholestasis | Q41142015 | ||
| Pruritus in cholestasis: No direct causative role for bile acid retention | Q41634480 | ||
| Rifampicin-induced elevation of serum bile acids in man. | Q41642560 | ||
| Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 | ||
| Serum bile acids in primary biliary cirrhosis | Q41876134 | ||
| Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. | Q43731043 | ||
| Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis | Q44004762 | ||
| Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease | Q44110715 | ||
| Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans | Q44162974 | ||
| Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial | Q44256491 | ||
| Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis | Q44330092 | ||
| Central mu-opioid receptors are down-regulated in a rat model of cholestasis | Q44331429 | ||
| The demography of primary biliary cirrhosis in Ontario, Canada | Q44439436 | ||
| Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
| Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise | Q45386103 | ||
| S-adenosylmethionine and affective disorder | Q48182854 | ||
| Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia | Q48396257 | ||
| Effects of central administration of opioids on facial scratching in monkeys | Q48454564 | ||
| Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis | Q49323238 | ||
| Cholestyramine in uraemic pruritus | Q50318025 | ||
| High prevalence of sleep disturbance in cirrhosis. | Q51099385 | ||
| Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. | Q51591921 | ||
| The incidence of pruritus after epidural morphine. | Q51748346 | ||
| Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. | Q52920374 | ||
| Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. | Q53527400 | ||
| Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. | Q53662990 | ||
| Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. | Q53674932 | ||
| Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. | Q53891814 | ||
| Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. | Q53923243 | ||
| Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. | Q53950071 | ||
| Epomediol ameliorates pruritus in patients with intrahepatic cholestasis of pregnancy. | Q55038108 | ||
| Effect of liver cirrhosis on the systemic availability of naltrexone in humans | Q58896381 | ||
| Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study | Q61854318 | ||
| A new method for the measurement of itch and the response to treatment | Q67337225 | ||
| Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas | Q68051353 | ||
| Primary biliary cirrhosis: clinicopathological characteristics and outcome | Q68386829 | ||
| Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study | Q68512879 | ||
| Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study | Q68781360 | ||
| The Presentation and Diagnosis of 100 Patients with Primary Biliary Cirrhosis | Q69302463 | ||
| Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin | Q69764185 | ||
| Naltrexone and hepatotoxicity | Q69880968 | ||
| Scratching during sleep | Q69999582 | ||
| Improvement of cholestatic pruritus by ondansetron | Q72218628 | ||
| Phototherapy for pruritus in primary biliary cirrhosis | Q72429266 | ||
| Cholestasis in the male rat is associated with naloxone-reversible antinociception | Q72503336 | ||
| The pruritus of cholestasis | Q72761756 | ||
| Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment | Q73043056 | ||
| Is fatigue associated with cholestasis mediated by altered central neurotransmission? | Q73043135 | ||
| Grip strength and subjective fatigue in patients with primary biliary cirrhosis | Q73812037 | ||
| Testosterone therapy for the pruritus of obstructive jaundice | Q74038480 | ||
| Open-label trial of oral nalmefene therapy for the pruritus of cholestasis | Q74310569 | ||
| Improved device for measuring scratching activity in patients with pruritus | Q74822700 | ||
| Primary biliary cirrhosis | Q75610531 | ||
| Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group | Q77221662 | ||
| Naltrexone in the treatment of alcohol dependence | Q77347366 | ||
| Fatigue in primary biliary cirrhosis | Q77586211 | ||
| Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial | Q77609350 | ||
| Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy | Q78100086 | ||
| Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study | Q78163535 | ||
| Serum-bile-acid levels in liver disease | Q78851327 | ||
| Experimental study of itch stimuli in animals | Q79494142 | ||
| P433 | issue | 4 | |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 879-900 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Clinics in liver disease | Q26842322 |
| P1476 | title | Pruritus and fatigue in primary biliary cirrhosis. | |
| P478 | volume | 7 |
| Q36076477 | Autonomic and sensory nerve dysfunction in primary biliary cirrhosis |
| Q36939998 | Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics |
| Q48331749 | Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. |
| Q33866454 | Concept on the pathogenesis and treatment of primary biliary cirrhosis |
| Q56974641 | Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease–like onset |
| Q43004194 | Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study |
| Q47805588 | Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial |
| Q37812845 | Hepatobiliary Manifestations of Gastrointestinal and Nutritional Disorders |
| Q33788252 | Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34904107 | Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q35681889 | Old Scratch |
| Q44736205 | Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy |
| Q26799175 | Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
Search more.